Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Malcolm I. Mitchell"'
Autor:
Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon
Publikováno v:
Drugs in Context, Pp 1-8 (2016)
Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to
Externí odkaz:
https://doaj.org/article/93831356d0004c618b43eff7688ea65b
Autor:
Mary Pat Knadler, William F. Annes, Amanda J. Long, Kathleen M. Hillgren, Jennifer Witcher, Y. Anne Pak, Malcolm I. Mitchell, Phillip Leese, Mosun Ayan-Oshodi
Publikováno v:
Drug Metabolism and Disposition
Despite peptide transporter 1 (PEPT1) being responsible for the bioavailability for a variety of drugs, there has been little study of its potential involvement in drug-drug interactions. Pomaglumetad methionil, a metabotropic glutamate 2/3 receptor
Publikováno v:
The Journal of Sexual Medicine. 13:187-193
Introduction Testosterone 2% solution (Axiron) applied to armpit(s) is used for replacement therapy in men with a deficiency of endogenous testosterone. Aim To determine the amount of testosterone on subjects' T-shirts 12 hours after applying testost
Autor:
Michael J. Detke, Graeme Eisenhofer, Jill Chappell, Robert A. Dean, Mary Pat Knadler, D. Richard Lachno, Malcolm I. Mitchell, Beth A. Pangallo, Smriti Iyengar, Evelyn D. Lobo, Charles B. Nemeroff, Harry Haber, Michael J. Owens
Publikováno v:
Journal of Clinical Psychopharmacology. 34:9-16
Duloxetine selectively inhibits the serotonin (5-HT) and norepinephrine (NE) transporters (5-HTT and NET, respectively), as demonstrated in vitro and in preclinical studies; however, transporter inhibition has not been fully assessed in vivo at the a
Publikováno v:
European Journal of Clinical Pharmacology
Purpose To assess the impact of hepatic or renal impairment on the pharmacokinetics (PK) of edivoxetine. Methods Two separate multi-center, open-label studies with males and females were conducted. Subjects were categorized according to their hepatic
Autor:
Ryan Wright, Jill Chappell, Malcolm I. Mitchell, Richard Kovacs, Harry Haber, Beth A. Pangallo, Michael J. Detke
Publikováno v:
Journal of Clinical Psychopharmacology. 33:236-239
A decrease in heart rate variability (HRV) can indicate increased sympathetic nervous system activity and possibly increased norepinephrine levels. In this randomized, placebo- and escitalopram (ESC)-controlled, subject-blind, 2-period, crossover stu
Autor:
Malcolm I. Mitchell, John H. April, Prajakti A. Kothare, Charles M. Beasley, Ling Jin, Harry Haber, Lynnette Kauffman, Corina Loghin, Albert J. Allen
Publikováno v:
British Journal of Clinical Pharmacology. 75:549-564
Aim The effects of atomoxetine (20 and 60 mg twice daily), 400 mg moxifloxacin and placebo on QTc in 131 healthy CYP2D6 poor metabolizer males were compared.
Autor:
David Smith, Johan Wallin, Dale R. Shepard, James J. Lee, Archana Chaudhary, Raffael Kurek, Patricia LoRusso, John D. Powderly, Grace Chao, Malcolm I. Mitchell, Wee Teck Ng, Gerrit Grau
Publikováno v:
Cancer chemotherapy and pharmacology. 78(2)
Necitumumab is a second-generation, recombinant, human immunoglobulin G1 monoclonal antibody that blocks the ligand binding site of the epidermal growth factor receptor. The primary objective of this phase 2 study, conducted in accordance with Intern
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 49:594-604
OBJECTIVE This was a singledose, randomized, positive- and placebo-controlled, double-dummy, double-blinded, 3-period crossover thorough QT study of exenatide, a glucagon-like peptide-1 receptor agonist for the treatment of Type 2 diabetes that enhan
Autor:
S. Stanley Young, Charles M. Beasley, Jessie Q. Xia, Charles Benson, Harry Haber, Corina Loghin, Malcolm I. Mitchell
Publikováno v:
Pacing and Clinical Electrophysiology. 34:1116-1127
Background: Many thorough QT (TQT) studies use a baseline day and double delta analysis to account for potential diurnal variation in QTc. However, little is known about systematic changes in the QTc across contiguous days when normal volunteers are